Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

accelerated-approval

14 stories tagged "accelerated-approval"

Drugs & FDA

Inovio's Accelerated-Approval Drug Is Headed for a $460,000 List Price, Matching the Rival the FDA Approved Outright

Inovio expects to list Voceryq at about $115,000 a dose, the same as Precigen's fully approved Papzimeos, then raised about $80.5 million in stock while the trial meant to confirm its benefit still lacks a final protocol.

Drugs & FDA

FDA Fast-Tracks a J&J Head and Neck Cancer Drug on Tumor Shrinkage, and Its Announcement Names No Confirmatory Trial

Tumors shrank in 42 percent of patients in a 102-person trial with no control arm. The FDA says clinical benefit is unconfirmed and confirmatory studies are required, and its announcement does not name one.

Drugs & FDA

Inovio Gets Its First FDA Approval After 7 of 26 Patients Went a Year Without Surgery

In December, the FDA's preliminary view was that Inovio hadn't justified the accelerated pathway. On Friday it granted it, on an uncontrolled trial whose confirmatory study still has no agreed protocol.

Cancer

Roche's KRAS Pill Beat the Older Drugs on Survival, an Endpoint Lumakras Never Won Against Chemotherapy

Median survival ran 17.7 months on divarasib and 12.0 on a control arm that was nine-tenths Lumakras, a drug whose own confirmatory trial showed no survival edge over chemotherapy.

Cancer

The Number Behind GSK's Rectal Cancer Approval Is 47 Percent, Not 76

Independent reviewers confirmed a year-long complete response in 54 of 116 AZUR-1 patients. GSK's release also carried an exploratory 76 percent. For a narrow slice of rectal cancer patients, the drug may still spare them radiation and surgery.

Drugs & FDA

The FDA Fast-Tracked GSK's Rectal Cancer Drug and Left the Trial's Own Scorecard Out of Its Announcement

Independent reviewers found 47 percent of evaluable AZUR-1 patients held a complete response for a year, the trial's registered endpoint. The FDA's announcement quoted friendlier measures instead.

Drugs & FDA

The FDA Approved a Breast Cancer Drug Its Own Advisers Had Just Rejected, 6 to 3

An FDA advisory panel voted 6 to 3 that AstraZeneca had not shown its breast cancer drug delivered a meaningful benefit. The agency approved it four months later anyway.

Drugs & FDA

The FDA Approved a Breast Cancer Drug Four Months After Its Advisers Voted No

On April 30 the FDA's oncology advisers voted 6 to 3 that AstraZeneca's camizestrant hadn't shown a clinically meaningful benefit. On September 4 the agency approved it anyway, conceding in its own approval that the benefit is "not yet confirmed."

Drugs & FDA

A $2.7 Million Gene Therapy, Approved Because Patients Needed Less Cornstarch

Ultragenyx's Genglycos won accelerated approval on a surrogate: a 31 percent cut in daily cornstarch. But the disease is low blood sugar, and by the company's own numbers the treated group spent slightly more time below 70 mg/dL, while liver enzymes spiked in 71 percent and every patient needed ster

Drugs & FDA

The FDA's Reviewers Called This Melanoma Data 'Not Interpretable.' Nine Days Later, the Agency Approved the Drug.

Twice the FDA rejected Replimune's engineered-herpes melanoma therapy, its reviewers calling the single-arm trial not interpretable. The design never changed. A 10-3 advisory vote came anyway, and nine days after that memo, the accelerated approval.

Drugs & FDA

The FDA Approved Moderna's mRNA Flu Shot for Seniors Without Proving It Works in Them

In February the FDA's own vaccine chief refused to even review it. One week later the agency reversed course, and the trial data never changed.

Drugs & FDA

The FDA Twice Called This Melanoma Trial Uninterpretable. Then It Approved the Drug, at $450,000 a Course.

Federal reviewers rejected Replimune's melanoma therapy twice, faulting a single-arm trial they called not adequate and well-controlled and its results uninterpretable. No new controlled data ever answered them. After a 10-3 advisory vote, the FDA approved it anyway, at $450,000 a course.

Drugs & FDA

FDA's New Gene Therapy Shortcut Leans on 'Platform Knowledge.' Six Months Ago, They Revoked Sarepta's After Three Patient Deaths.

FDA's new gene therapy draft guidance invites sponsors to lean on "platform knowledge" to streamline submissions, six months after the agency revoked Sarepta's AAVrh74 platform designation following three patient deaths.

Drugs & FDA

Hepatitis Delta Has Waited Forty-Nine Years for a Drug. The FDA Made American Patients Wait Three Extra.

The FDA cleared bulevirtide for chronic hepatitis delta this week, six years after Europe started using it and three years after a U.S. application was turned down on manufacturing grounds. The wait is its own story.